PharmaEngine (ROCO:4162) Inventories, Raw Materials & Components: NT$0.0 Mil (As of Dec. 2025)


ROCO:4162 PharmaEngine Inc ROCO:4162
78 GF Score
Price NT$63.70
GF Value NT$115.21
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PharmaEngine Inventories, Raw Materials & Components?

PharmaEngine ROCO:4162 +4.43% 78 Inventories, Raw Materials & Components is NT$0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:4162 with a GF Score™ of 78/100 and a GF Value™ of NT$115.21 (Significantly Undervalued). The stock has 3 warning signs investors should review.

PharmaEngine's inventories, raw materials & components for the quarter that ended in Dec. 2025 was NT$0.0 Mil.

PharmaEngine Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for PharmaEngine's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaEngine Inventories, Raw Materials & Components Chart

PharmaEngine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PharmaEngine Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4162
78GF Score
PharmaEngine Inc ROCO:4162
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEngine Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of NT$0.0 Mil mean?
PharmaEngine (ROCO:4162) has a Inventories, Raw Materials & Components of NT$0.0 Mil as of Dec. 2025. Raw materials are the components a company uses for its main products. View historical data on PharmaEngine and its competitors.
Is PharmaEngine's Inventories, Raw Materials & Components too high?
PharmaEngine's current Inventories, Raw Materials & Components is NT$0.0 Mil. Overall, PharmaEngine has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Inventories, Raw Materials & Components compare to VRTX and REGN?
PharmaEngine's Inventories, Raw Materials & Components of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on PharmaEngine and its competitors. PharmaEngine's current Inventories, Raw Materials & Components is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.21, compared to a current price of NT$63.70 — trading 44.7% below its estimated fair value. The current Inventories, Raw Materials & Components is NT$0.0 Mil. PharmaEngine's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Inventories, Raw Materials & Components is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$63.70 is trading 44.7% below its estimated GF Value™ of NT$115.21. GuruFocus considers PharmaEngine to be Significantly Undervalued.

Key valuation signals for ROCO:4162:

  • Inventories, Raw Materials & Components: NT$0.0 Mil
  • GF Value™: NT$115.21 vs. price of NT$63.70 (44.7% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
78GF Score

Get the complete analysis for ROCO:4162

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$63.70
Price
NT$115.21
GF Value